NEURONAL NUCLEAR IGG ANTIBODY BY IFA WITH REFLEX TO TITER & IMMUNOBLOT, SERUM
- NEURONAL NUCLEAR IGG ANTIBODY BY IFA WITH REFLEX TO TITER & IMMUNOBLOT, SERUM
- Start Date
- Expiration Date
- ANNA; Hu; Ri
- CPT Codes
- 86255, If reflexed add: 86256, 83516
- Reference Test
- Transport Info
Centrifuge and immediately transfer serum to separate plastic tube
- Fasting Required?
- Patient Instructions
- Reference Range
ANNA antibodies are screened by IFA. If the IFA screen is 1:10, then a titer and immunoblot (Hu and Ri) will be added. Additional charges apply.
Semi-Quantitative Indirect Fluorescent Antibody (IFA)
ANNA-1 (anti-Hu) and ANNA-2 (anti-Ri) are screened by immunofluorescence and confirmed by immunoblot detection of antibody reactive with a 35-40 kDa (ANNA-1) or a 55 kDa (ANNA-2) neuronal protein. ANNA-1 is present in patients with paraneoplastic syndromes (paraneoplastic sensory neuropathy or paraneoplastic encephalomyelitis) most commonly associated with small-cell lung carcinoma (SCLC). ANNA-2 is present in patients with midbrain encephalitis, cerebellar ataxia, eye movement disorders (usually opsoclonus), and occasionally myelopathy. Neoplasms most often associated with ANNA-2 are breast carcinoma and SCLC. ANNA-1 and ANNA-2 may be detectable before the associated neoplasm is detectable.
ANNA antibodies are screened by IFA. If the IFA screen shows reactivity at 1:10, the specimen will be titered to endpoint and confirmed (Hu or Ri) by immunoblot.